Tag: lung cancer

1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete ...

1. The overall progression-free survival (PFS) was 10.54 years. 2. Patients with body mass weight (BMI) ≥ 24 derived greater ...

1. The median disease-free survival for gefitinib group and cisplatin/vinorelbine group was 35.9 and 25.1 months, respectively. 2. Patients receiving ...

Click to read this study in JAMA Otolaryngology - Head & Neck Surgery. 

Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. Grade 3 ...

1. Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. 2. ...

1. Hypofractionated image-guided radiotherapy was not superior to conventionally fractionated radiotherapy monotherapy for patients with stage II/III non-small cell lung ...

1. Postoperative radiotherapy for pIIIA-N2 non-small cell lung cancer did not improve disease-free survival or overall survival, but did improve ...

1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, ...

1. Tislelizumab, a monoclonal antibody and PD1/L1 inhibitor, when combined with chemotherapy, showed significantly prolonged progression free survival and higher ...